MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/healthcare14111559

Медицинская библиотека · Healthcare (Basel, Switzerland) · 2026

Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation.

Dorval Michel, Audet-Croteau Virginie, Chang Sue-Ling, Masse-Grenier Marianne, Tremblay Annie, Bénard Elodie, Chapdelaine Alexandra, Garel Nicolas, Guertin Jason Robert

СтатьяПеревод в очереди

Аннотация

Background/

Objectives

Psilocybin-assisted therapy (PAT) is a promising intervention to alleviate existential distress among patients with advanced cancer receiving palliative care. However, evidence on how to integrate PAT into routine oncology and palliative care services remains scarce. This study aimed to examine real-world PAT implementation, identify factors influencing adoption, and estimate integration costs within oncology and palliative care services.

Methods

We conducted a single-case implementation study in a large university-affiliated tertiary care center in Canada during the first year following its introduction. Semi-structured interviews with clinicians, managers, and other stakeholders explored barriers, facilitating conditions, and actions needed to support PAT implementation. A budget impact analysis estimated incremental costs associated with delivering PAT.

Results

After one year, no patients had received PAT. Ten professionals representing diverse clinical and managerial roles participated in the interviews. While participants viewed PAT favorably, they emphasized the need to align the intervention with existing care pathways and clarify referral processes. Administrative and regulatory procedures, together with logistical constraints related to treatment delivery, were identified as key barriers, whereas perceived clinical relevance and institutional leadership were seen as important facilitators. From the health care system perspective, the estimated cost of delivering a complete PAT intervention ranged from 2648 to 5827 Canadian dollars (CAD) per patient, depending on the scenario examined, excluding the cost of the psilocybin itself.

Conclusions

Despite perceived clinical relevance and relatively modest estimated costs, the absence of treated patients after one year highlights the gap between regulatory authorization and effective service uptake. These findings underscore the importance of structured implementation strategies, sustained institutional support, and alignment between regulatory frameworks and clinical workflows to ensure meaningful integration of PAT into routine oncology and palliative care services.

Для цитирования: Dorval Michel, Audet-Croteau Virginie, Chang Sue-Ling, Masse-Grenier Marianne, Tremblay Annie, Bénard Elodie, Chapdelaine Alexandra, Garel Nicolas, Guertin Jason Robert. Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World Implementation.. Healthcare (Basel, Switzerland). 2026. DOI: 10.3390/healthcare14111559.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.